scholarly journals Metabolic Syndrome in Polycystic Ovary Syndrome

2021 ◽  
pp. 1-11
Author(s):  
Yun-Chiao Hsieh ◽  
Po-Kai Yang ◽  
Mei-Jou Chen
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Treatment Strategies ◽  
Vascular Diseases ◽  
Reproductive Age ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome ◽  
Ovarian Morphology ◽  
The Many

Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women of reproductive age. Although its essential clinical manifestation includes a plethora of symptoms and signs, which largely reflects the underlying hyperandrogenism, oligo/anovulation, and polycystic ovarian morphology, PCOS may also be associated with many metabolic derangements. These metabolic derangements happen to overlap with many of the core constituents of the metabolic syndrome (MBS)—increased insulin resistance, central obesity, and dyslipidemia. The two disorders also display similarly increased risks for certain metabolic and vascular diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Due to the many similarities between metabolic syndrome and PCOS, this review aims to examine the evidence concerning the overlapping features, the risks for comorbidities, possible shared mechanisms, and treatment strategies in patients with coexisting PCOS and MBS.

Polycystic ovary syndrome: reproductive aspects

2011 ◽  
pp. 1229-1234
Author(s):  
Sophie Catteau-Jonard ◽  
Cécile Gallo ◽  
Didier Didier
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Therapeutic Approaches ◽  
Women Of Reproductive Age ◽  
Ovary Syndrome ◽  
Common Cause ◽  
The Metabolic Syndrome

The polycystic ovary syndrome (PCOS) is the most common cause of anovulation and hyperandrogenism in women, affecting between 5 and 10% of women of reproductive age worldwide (1). Although this difficult topic in endocrine gynaecology is under extensive research, controversies still remain about the pathophysiology, diagnosis, and therapy of PCOS. The PCOS phenotype can be structured in three components: manifestations of anovulation, hyperandrogenism, and the metabolic syndrome (of which hyperinsulinaemia secondary to insulin resistance is the central abnormality). The latter two are addressed in other chapters. Our knowledge about the mechanism of disturbed folliculogenesis in PCOS that is responsible for its reproductive aspects has much increased these last years, thus opening new avenues for the diagnostic and therapeutic approaches.

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up

2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome ◽  
Previous Diagnosis ◽  
Long Term Follow Up

scholarly journals A study on the clinical, biochemical and hormonal profile of polycystic ovary syndrome patients attending tertiary care hospital

2017 ◽  
Vol 6 (5) ◽  
pp. 1986
Author(s):  
Spandana J. C. ◽  
Prasanna Kumar Shetty K. ◽  
Prasanna Kumar Shetty K.
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Genetic Disorder ◽  
Reproductive Age ◽  
Care Hospital ◽  
Observation Study ◽  
Ovary Syndrome ◽  
Hormonal Profile ◽  
Waist Hip Ratio

Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorder of reproductive age affecting 5% to 10% of women worldwide. It is a heterogenous, multifactorial, complex genetic disorder. PCOS receives a considerable attention because of its high prevalence and metabolic, reproductive and cardiovascular consequences.Methods: A cross sectional observation study of 100 PCOS patients was carried out between January 2014 to July 2015 in Gynaecology out-patient and Infertility OPD, Justice K. S. Hegde charitable hospital, Mangalore. The clinical, biochemical and hormonal profile of these patients were analysed and correlation was done between clinical features and biochemical and hormonal profile.Results: The prevalence of PCOS was 6.3% in the Gynaecology out-patient visits and 37.14% among infertile women. Menstrual irregularity was the most common complaint accounting for 31% followed by infertility (23%). Elevated leutinizing hormone and elevated LH: FSH was significant in irregular menstrual group. The prevalence of metabolic syndrome in our study was 21.3%. Spearmans correlation between various clinical and laboratory parameters showed menstrual cycle and body mass index(BMI) had a fair positive correlation and was significant. WHR (waist hip ratio) showed 21 times risk for metabolic syndrome.Conclusions: The study showed that most of our polycystic ovary syndrome subjects were hirsute, with central obesity and overweight or obese. Oligomenorrhea was the most common presentation. Among the various risk factors studied, WHR (waist hip ratio) showed 21 times risk for metabolic syndrome. Obese women with PCOS had more severe ovulatory dysfunction and need more attention for their appropriate management.

Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: Using the International Diabetes Federation criteria

2007 ◽  
Vol 23 (3) ◽  
pp. 153-160 ◽  
Author(s):  
Sawaek Weerakiet ◽  
Pongamon Bunnag ◽  
Bunyong Phakdeekitcharoen ◽  
Surapee Wansumrith ◽  
Suwannee Chanprasertyothin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
International Diabetes Federation ◽  
Asian Women ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome

The Metabolic Syndrome in Polycystic Ovary Syndrome

2007 ◽  
Vol 50 (1) ◽  
pp. 205-225 ◽  
Author(s):  
PAULINA A. ESSAH ◽  
EDMOND P. WICKHAM ◽  
JOHN E. NESTLER
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome

scholarly journals The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Eduardo Spinedi ◽  
Daniel P. Cardinali
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Adipose Tissue ◽  
Polycystic Ovary Syndrome ◽  
White Adipose Tissue ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome ◽  
Obstructive Sleep ◽  
The Impact

Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism are very common features of the polycystic ovary syndrome phenotype. Dysfunctional white adipose tissue has been identified as a major contributing factor for insulin resistance in polycystic ovary syndrome. Environmental (e.g., chronodisruption) and genetic/epigenetic factors may also play relevant roles in syndrome development. Overweight and/or obesity are very common in women with polycystic ovary syndrome, thus suggesting that some polycystic ovary syndrome and metabolic syndrome female phenotypes share common characteristics. Sleep disturbances have been reported to double in women with PCOS and obstructive sleep apnea is a common feature in polycystic ovary syndrome patients. Maturation of the luteinizing hormone-releasing hormone secretion pattern in girls in puberty is closely related to changes in the sleep-wake cycle and could have relevance in the pathogenesis of polycystic ovary syndrome. This review article focuses on two main issues in the polycystic ovary syndrome-metabolic syndrome phenotype development: (a) the impact of androgen excess on white adipose tissue function and (b) the possible efficacy of adjuvant melatonin therapy to improve the chronobiologic profile in polycystic ovary syndrome-metabolic syndrome individuals. Genetic variants in melatonin receptor have been linked to increased risk of developing polycystic ovary syndrome, to impairments in insulin secretion, and to increased fasting glucose levels. Melatonin therapy may protect against several metabolic syndrome comorbidities in polycystic ovary syndrome and could be applied from the initial phases of patients’ treatment.

Sign in / Sign up

Export Citation Format

Share Document